LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Elenco Azioni・Coherus Oncology Inc

Coherus Oncology Inc

Chiusa

SettoreSettore sanitario

1.41 -0.7

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.41

Massimo

1.48

Metriche Chiave
By Trading Economics
Entrata	-278M -37M
Vendite	-438K 12M
P/E Media del settore	3.509 49.052
EPS	-0.25
Margine di Profitto	-300.041
Dipendenti	145
EBITDA	7.9M -35M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+468.97% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-40M 219M
Apertura precedente	2.11
Chiusura precedente	1.41

Notizie sul Sentiment di mercato

By Acuity

100%

315 / 344 Classifica in Healthcare

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 giu 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 giu 2026, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 giu 2026, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 giu 2026, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 giu 2026, 20:51 UTC

Utili

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 20:09 UTC

Discorsi di Mercato

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 giu 2026, 19:36 UTC

Discorsi di Mercato

Cattle Climbs as Crude Oil Falls -- Market Talk

9 giu 2026, 19:32 UTC

Discorsi di Mercato

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 giu 2026, 19:25 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 giu 2026, 19:00 UTC

Discorsi di Mercato

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 giu 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 giu 2026, 18:47 UTC

Discorsi di Mercato

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 giu 2026, 18:37 UTC

Discorsi di Mercato

Canada's Cooling Trade With the U.S. -- Market Talk

9 giu 2026, 18:27 UTC

Discorsi di Mercato

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 giu 2026, 17:35 UTC

Discorsi di Mercato

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 giu 2026, 17:30 UTC

Discorsi di Mercato

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 giu 2026, 16:34 UTC

Discorsi di Mercato

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 giu 2026, 15:28 UTC

Discorsi di Mercato

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 giu 2026, 15:25 UTC

Discorsi di Mercato

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

468.97% in crescita

Previsioni per 12 mesi

Media 8.25 USD 468.97%

Alto 12 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

315 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.